Provided by Tiger Trade Technology Pte. Ltd.

Belite Bio, Inc.

155.09
-0.6200-0.40%
Volume:42.20K
Turnover:6.53M
Market Cap:6.25B
PE:-56.64
High:156.80
Open:155.98
Low:153.85
Close:155.71
52wk High:200.00
52wk Low:62.18
Shares:40.27M
Float Shares:19.38M
Volume Ratio:0.45
T/O Rate:0.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7382
EPS(LYR):-2.3141
ROE:-22.10%
ROA:-15.65%
PB:8.04
PE(LYR):-67.02

Loading ...

Cantor Fitzgerald Reaffirms Their Buy Rating on Belite Bio, Inc. ADR (BLTE)

TIPRANKS
·
Aug 12

Belite Bio Price Target Raised to $214.00/Share from $200.00 by HC Wainwright & Co.

Dow Jones
·
Aug 12

Belite Bio, Inc : H.c. Wainwright Raises Target Price to $214 from $200

THOMSON REUTERS
·
Aug 12

Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease NDA

Reuters
·
Aug 12

Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1

THOMSON REUTERS
·
Aug 12

Belite Bio - FDA Sets Pdufa Date of February 12, 2027 for Tinlarebant Nda

THOMSON REUTERS
·
Aug 12

Belite Bio, Inc Expected to Post a Loss of 79 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Belite Bio, Inc Expected to Post a Loss of 79 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results

GlobeNewswire
·
Aug 06

3 U.S. Drug Manufacturing Stocks Investors Are Watching As Tariffs Rise

Simply Wall St.
·
Jul 22

Will Tinlarebant’s First-in-Disease Data and FDA Filing Change Belite Bio’s (BLTE) Narrative?

Simply Wall St.
·
Jul 20

Belite Bio Announces Oral Presentation at the Asrs Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

THOMSON REUTERS
·
Jul 20

Belite Bio - Tinlarebant Well Tolerated in Phase 3 Dragon Trial

THOMSON REUTERS
·
Jul 20

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

GlobeNewswire
·
Jul 20

Belite Bio Joins H.C. Wainwright Ophthalmology Virtual Conference Panel July 22

Reuters
·
Jul 15

Mizuho Securities Sticks to Their Buy Rating for Belite Bio, Inc. ADR (BLTE)

TIPRANKS
·
Jul 13

How Phase 3 DRAGON Trial Data Showcases At Major Conferences At Belite Bio (BLTE) Has Changed Its Investment Story

Simply Wall St.
·
Jul 08

Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium

GlobeNewswire
·
Jul 06

Belite Bio to Present Phase 3 Dragon Tinlarebant Topline Results at ISCEV Symposium

Reuters
·
Jul 06

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

GlobeNewswire
·
Jul 06